A nasal composition is provided comprising or consisting of a first composition part in the form of a liquid for nasal application to a patient in use, and a second composition part in the form of a powder for nasal application to the patient in use. The first and second composition parts are applied to the patient separately or together as required.

A PEGylated polymer is disclosed according to Formula 1 wherein n is any integer from 4 to 200 monomers, and R is a polymer chain comprising a 4 to 200-monomer moiety.

The present disclosure provides methods of using and pharmaceutical compositions of tacrolimus that may be administered by inhalation once a day. These methods and compositions may be used to generate a blood plasma concentration of tacrolimus in a therapeutically effective range using only a single dose daily. Administration once daily may result in few adverse events and reduced side effects while increasing patient compliance.

The application is directed a composition comprising organic acid (e.g., ascorbic acid), glutathione, a glutathione derivative, a glutathione conjugate, a pharmaceutically-acceptable salt thereof, or any combination thereof, and methods of using the same. In certain aspects the application is directed to glutathione, a glutathione derivative, a glutathione conjugate, a pharmaceutically-acceptable salt thereof; and an organic acid; wherein the molar ratio is about 0.5-1:1. The composition can further comprises a bicarbonate salt, wherein the molar ratio is about 0.1-0.5:0.5-1:1.

The present invention includes compositions and methods for making and using a rapid dissolving, high potency, substantially amorphous nanostructured aggregate for pulmonary delivery of tacrolimus and a stabilizer matrix comprising, optionally, a polymeric or non-polymeric surfactant, a polymeric or non-polymeric saccharide or both, wherein the aggregate comprises a surface area greater than 5 m.sup.2/g as measured by BET analysis and exhibiting supersaturation for at least 0.5 hours when 11-15-times the aqueous crystalline solubility of tacrolimus is added to simulated lung fluid.

The present invention relates to a pharmaceutically acceptable acid addition salt of: (i) 9,10-dimethoxy-2-(2,4,6-tri-methylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one (RPL554); and (ii) ethane-1,2-disulfonic acid, ethanesulfonic acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, hydrochloric acid, hydrobromic acid, phosphoric acid or sulfuric acid.

The present invention relates to methods and compositions for the treatment and prophylaxis of pulmonary arterial hypertension (PAH) in a human subject in need of such treatment, the methods comprising the pulmonary administration to the subject, preferably via inhalation of a composition comprising rapamycin or a prodrug or derivative thereof.

A dry powder inhaler including replaceable cartridges containing a dry powder for local or systemic delivery through the pulmonary tract and lungs is disclosed. The inhalers are used with inhalable dry powders, including medicament formulations comprising active agents for local or systemic delivery and for the treatment of diseases such as, pulmonary hypertension, cardiovascular disease, anaphylaxis, diabetes, obesity, cancer, and other diseases, or symptoms associated with these and other diseases, such as nausea, vomiting, pain and inflammation.

The present disclosure generally relates to a process for manufacturing a microparticle composite or a dry powder inhaler composition of polymyxin and CFTR activator or CFTR potentiator comprising the steps preparing a suspension of nanoparticles (NPs) of CFTR activator or CFTR potentiator or their combinations; mixing the suspension of NPs with a solution of polymyxin and a solution of leucine, then followed by drying to afford said micro-particle composite or dry powder inhaler composition. Pharmaceutical compositions and methods for treating a patient of cystic fibrosis (CF) and/or a lung infection are within the scope of this invention.

In one aspect, the disclosure relates to pharmaceutical compositions comprising one or more cannabinoids and methods of treating and preventing migraine using the same. In one aspect, the pharmaceutical compositions can be formulated for administration by inhalation in order to rapidly access endogenous cannabinoid receptors while avoiding systemic side effects associated with oral or other routes of administration.